Bayer AG's stock exhibited a cautiously positive trend in Wednesday's trading, navigating within a narrow range of €21.28 to €21.77 on XETRA. The trading volume remained substantial with over 2.4 ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. For the quarter ended December ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Bayer's most recent financial performance has ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Drilling at Alma Metals and Canterbury Resources' Briggs asset uncovered near surface, high-grade copper and molybdenum ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

According to Yahoo!Finance, Bayer’s market cap has fallen more than 44% this year. The stock price hit a 20-year low last November. Slashing management jobs, in Bayer’s case, didn’t yield ...

Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage pharmaceutical company committed to developing, commercializing, and ...